Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: ...

Reviewing PFE’s five-year history, the stock has experienced a balanced 50-50 distribution of positive and negative returns ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Pfizer has been paying dividends for 35 years and raising them for 14 years. Read more to see whether PFE stock is a buy.

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Last week, Pfizer announced that it would no longer develop danuglipron, a daily GLP-1 weight-loss drug which investors were ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...